ScreenerHero

PYPD PolyPid Ltd.

NAS · US · Healthcare · Biotechnology · polypid.com
4.950USD-3.51%Mkt Cap: 100.54M $P/E: —

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap100.54M USD
Enterprise Value99.21M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.17M USD
Revenue/Share—
Last Price4.950 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.18
PEG—
EV/EBITDA-3.29
EV/Revenue—
P/S—
P/B19.36
EPS (TTM)-1.44
EPS (Forward)-1.23
52W Range
3.06071% of range5.730
52W High5.730 USD
52W Low3.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-311.39%
ROA-153.18%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.88M USD
CapEx (TTM)210.00K USD
FCF Margin—
FCF Yield-17.27%
Net Debt-4.99M USD
Net Debt/EBITDA0.17
Balance Sheet
Debt/Equity0.25
Current Ratio1.35
Quick Ratio0.99
Book Value/Sh0.27 USD
Cash/Share0.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateSep 21, 2023
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.75 USD
Upside (mean)+137.4%
Target Range8.000 USD – 14.00 USD
8.000+137.4% to mean14.00
# Analysts4
Ownership
Shares Out.20.31M
Float12.16M
Insiders12.34%
Institutions34.55%
Short Interest
Short Ratio1.1d
Short % Float0.86%
Short % Out.0.64%
Shares Short130.35K
Short (prev mo.)231.38K
Technical
SMA 504.976 (-0.5%)
SMA 2004.647 (+6.5%)
Beta1.38
S&P 52W Chg15.78%
Avg Vol (30d)107.76K
Avg Vol (10d)87.88K
Technical Indicators
RSI (14)42.7
MACD0.0338
MACD Signal0.0837
MACD Hist.-0.0500
BB Upper5.475 USD
BB Middle5.247 USD
BB Lower5.019 USD
BB Width8.68%
ATR (14)0.2605 USD
Vol Ratio (20d)1.25x